var data={"title":"Paromomycin: Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Paromomycin: Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/6726?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=paromomycin-patient-drug-information\" class=\"drug drug_patient\">see &quot;Paromomycin: Patient drug information&quot;</a> and <a href=\"topic.htm?path=paromomycin-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Paromomycin: Pediatric drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F206519\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Humatin</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F206540\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Amebicide</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F206520\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Hepatic coma:</b> Oral: 4 g daily in divided doses (at regular intervals) for 5 to 6 days</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Intestinal amebiasis:</b> Oral: 25 to 35 mg/kg/day in 3 divided doses for 5 to 10 days</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Cryptosporidiosis-associated diarrhea in HIV-infected patients (off-label use):</b> Oral: 500 mg 4 times daily for 14 to 21 days (must be used in conjunction with optimized ART, electrolyte replacement, and symptomatic treatment and rehydration) (HHS [OI adult 2015])</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Dientamoeba fragilis</i> (off-label use):</b> Oral: 25 to 35 mg/kg/day in 3 divided doses for 7 days (CDC 2012)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F206531\" class=\"block dop drugH1Div\"><span class=\"drugH1\">Dosing: Pediatric</span><p>(For additional information <a href=\"topic.htm?path=paromomycin-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Paromomycin: Pediatric drug information&quot;</a>)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Intestinal amebiasis (acute and chronic):</b> Children and Adolescents: Refer to adult dosing.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Cryptosporidiosis-associated diarrhea in HIV-infected patients (off-label use):</b> Adolescents: Refer to adult dosing.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Dientamoeba fragilis</i> (off-label use):</b> Children and Adolescents: Oral: 25-35 mg/kg/day in 3 divided doses for 7 days (CDC 2012; Vandenberg 2006)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F206521\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F22125160\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">No dosage adjustment provided in the manufacturer&rsquo;s labeling (has not been studied).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F22125161\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">No dosage adjustment provided in the manufacturer&rsquo;s labeling (has not been studied).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F206506\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Capsule, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 250 mg</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F206493\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">Yes</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F23355138\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">Administer orally with meals.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F206507\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Intestinal amebiasis:</b>  Treatment of acute and chronic intestinal amebiasis (not effective for extraintestinal amebiasis).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Hepatic coma:</b>  Management (adjunctive) of hepatic coma.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25470348\" class=\"block off-label drugH1Div\"><span class=\"drugH1\">Use: Off-Label</span>\n    <p>Cryptosporidiosis-associated diarrhea in HIV-infected patients (adolescents and adults); Dientamoeba fragilis infection (adults, children)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F206500\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">1% to 10%: Gastrointestinal: Abdominal cramps, diarrhea, heartburn, nausea, vomiting </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">&lt;1%, postmarketing, and/or case reports: Enterocolitis (secondary), eosinophilia, headache, ototoxicity, pruritus, steatorrhea, vertigo</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F206510\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">Hypersensitivity to paromomycin or any component of the formulation; intestinal obstruction</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F206497\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Superinfection: Prolonged use may result in fungal or bacterial superinfection, including <i>C. difficile</i>-associated diarrhea (CDAD) and pseudomembranous colitis; CDAD has been observed &gt;2 months postantibiotic treatment.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Renal impairment: Use with caution in patients with renal impairment.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Ulcerative bowel lesions: Use with caution in patients with ulcerative bowel lesions; may lead to renal toxicity due to inadvertent absorption.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Appropriate use: Use in the absence of proven (or strongly suspected) susceptible infection is unlikely to provide benefit and may increase the risk for drug-resistance.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13299825\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F206502\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=9742&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:0em;display:inline\">There are no known significant interactions.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F10236736\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Paromomycin is poorly absorbed when given orally. Information related to the use of paromomycin in pregnancy is limited (Kreutner 1981). Use may be considered for the treatment of giardiasis throughout pregnancy (Gardner 2001) or cryptosporidiosis after the first trimester (DHHS 2013) in pregnant women.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F206512\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Paromomycin is poorly absorbed when given orally. Available information suggests that paromomycin may be used in nursing women when renal function is normal in both the mother and infant (Davidson 2009).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F206496\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Acts directly on ameba; has antibacterial activity against normal and pathogenic organisms in the GI tract; interferes with bacterial protein synthesis by binding to 30S ribosomal subunits</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F206509\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Absorption: Poor oral absorption</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Excretion: Feces (~100% as unchanged drug)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16323618\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Capsules</b> (Paromomycin Sulfate Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">250 mg (100): $567.00</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6038719\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Ameparomo (JP);</li>\n      <li>Aminosidine (JP);</li>\n      <li>Gabbromycin (KR);</li>\n      <li>Gabbroral (BE, IT, LU);</li>\n      <li>Gabbryl (ID);</li>\n      <li>Gabrosidina (CR, DO, GT, HN, NI, PA, SV);</li>\n      <li>Humagel (FR);</li>\n      <li>Humatin (AT, CH, DE, ES, IT);</li>\n      <li>Lumenex (CR, DO, GT, HN, NI, PA, SV);</li>\n      <li>Neotinil (CR, DO, GT, HN, NI, PA, SV);</li>\n      <li>Septoral (CR, DO, GT, HN, NI, PA, SV)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Centers for Disease Control and Prevention: Parasites &ndash; Dientamoeba fragilis (resources for health professionals); 2012. Available at <a href=\"http://www.cdc.gov/parasites/dientamoeba/health_professionals/index.html\" target=\"_blank\">http://www.cdc.gov/parasites/dientamoeba/health_professionals/index.html</a>. Accessed January 7, 2014.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Davidson RN, den Boer M, Ritmeijer K. Paromomycin. <i>Trans R Soc Trop Med Hyg</i>. 2009; 103(7):653-660.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/paromomycin-drug-information/abstract-text/18947845 /pubmed\" target=\"_blank\" id=\"18947845 \">18947845 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    HHS Panel on Opportunistic Infections in HIV-Infected Adults and Adolescents. Guidelines for the prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from the Centers for Disease Control and Prevention, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. September 2015. Available at <a href=\"http://aidsinfo.nih.gov/contentfiles/lvguidelines/adult_oi.pdf\" target=\"_blank\">http://aidsinfo.nih.gov/contentfiles/lvguidelines/adult_oi.pdf</a>. Accessed October 8, 2015</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Liu LX and Weller PF. Antiparasitic Drugs. <i>N Engl J Med</i>. 1996;334(18):1178-1184.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/paromomycin-drug-information/abstract-text/8602186/pubmed\" target=\"_blank\" id=\"8602186\">8602186</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Paromycin sulfate capsules [package insert]. Edison, NJ: Heritage Pharmaceuticals; June 2012.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    US Department of Health and Human Services Panel on Opportunistic Infections in HIV-Infected Adults and Adolescents. Guidelines for the prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from the Centers for Disease Control and Prevention, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. <a href=\"http://aidsinfo.nih.gov/contentfiles/lvguidelines/adult_oi.pdf\" target=\"_blank\">http://aidsinfo.nih.gov/contentfiles/lvguidelines/adult_oi.pdf</a>. Updated September 24, 2015. Accessed September 25, 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"17195717\"></a>Vandenberg O, Souayah H, Mouchet F, et al. Treatment of Dientamoeba fragilis infection with paromomycin. <i>Pediatr Infect Dis J</i>. 2007;26(1):88-90.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/paromomycin-drug-information/abstract-text/17195717/pubmed\" target=\"_blank\" id=\"17195717\">17195717</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 9742 Version 93.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F206519\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F206540\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F206520\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Pediatric\" href=\"#F206531\" class=\"outlineLink\">Dosing: Pediatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F206521\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F22125160\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F22125161\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F206506\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F206493\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F23355138\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F206507\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Use: Off-Label\" href=\"#F25470348\" class=\"outlineLink\">Use: Off-Label</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F206500\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F206510\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F206497\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13299825\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F206502\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F10236736\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F206512\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F206496\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F206509\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F16323618\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F6038719\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/9742|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=paromomycin-patient-drug-information\" class=\"drug drug_patient\">Paromomycin: Patient drug information</a></li><li><a href=\"topic.htm?path=paromomycin-pediatric-drug-information\" class=\"drug drug_pediatric\">Paromomycin: Pediatric drug information</a></li></ul></div></div>","javascript":null}